Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
| Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
| PD-1+VEGF bsAb | Bispecific antibody | Oncology/Cancer | Solid tumor | Phase I | Global (except China) |
| 제품번호 | 종 | 제품 설명 | 구조 | 순도 | 특징 |
|---|---|---|---|---|---|
| VE0-H52H3 | Human | Human VEGF110 Protein, His Tag (MALS verified) |  |
|
|
| VE0-H5212 | Human | Human VEGF110 Protein, premium grade |  |
|
Human VEGFR1/R2 captured on Protein A Chip can bind Human VEGF110 Protein, His Tag (Cat. No. VE0-H52H3) with an affinity constant of 13.8 pM as determined in a SPR assay (Biacore 8K) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Ranibizumab biosimilar (Intas Biopharmaceuticals) | Approved | Intas Biopharmaceuticals | Razumab | India | Macular Degeneration | Intas Biopharmaceuticals | 2015-01-01 | Macular Degeneration | Details | |
| Bevacizumab biosimilar (Dr. Reddy's Laboratories) | Approved | Dr Reddy's Laboratories Ltd | Versavo | India | Glioblastoma; Carcinoma, Renal Cell; Peritoneal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms | Dr Reddy's Laboratories Ltd | 2019-08-19 | Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details | |
| Bevacizumab biosimilar (Zydus Cadila) | Approved | Zydus Cadila | Bryxta | India | Carcinoma, Non-Small-Cell Lung | Zydus Cadila | 2017-01-01 | Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Peritoneal Neoplasms; Metastatic breast cancer; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| Bevacizumab biosimilar(Apotex ) | Approved | Apotex Inc | BAMBEVI | Canada | Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Glioblastoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Apotex Inc | 2021-09-23 | Carcinoma, Ovarian Epithelial; Glioblastoma; Peritoneal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| Bevacizumab biosimilar (Reliance Life Sciences) | R-TPR-023 | Approved | Reliance Life Sciences | BevaciRel | India | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Carcinoma, Renal Cell; Uterine Cervical Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Reliance Life Sciences Pvt Ltd | 2016-06-13 | Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Bevacizumab biosimilar (AryoGen Biopharma) | BE1040V | Approved | Aryogen Biopharma | Stivant | Iran | Glioblastoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Uterine Cervical Neoplasms; Metastatic breast cancer; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Aryogen Biopharma | 2019-06-01 | Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Peritoneal Neoplasms; Metastatic breast cancer; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Bevacizumab biosimilar (Intas Pharmaceuticals) | INTP-24 | Approved | Intas Biopharmaceuticals | Bevatas | India | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Uterine Cervical Neoplasms; Glioblastoma; Breast Neoplasms | Intas Biopharmaceuticals | 2017-10-04 | Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Bevacizumab biosimilar (Biocad) | BCD-021 | Approved | Biocad | Avegra | Russian Federation | Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Breast Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Uterine Cervical Neoplasms; Glioblastoma; Carcinoma, Renal Cell | Biocad | 2015-11-25 | Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Bevacizumab biosimilar (Elea) | Approved | Laboratorio Elea Phoenix Sa | Lumiere | Argentina | Macular Degeneration | Laboratorio Elea Phoenix Sa | 2018-04-26 | Macular Degeneration | Details | |
| Ranibizumab biosimilar (Senju) | GBS-007; OT-701; SJP-0133 | Approved | Senju Pharmaceutical Co Ltd | Japan | Macular Degeneration | Senju Pharmaceutical Co Ltd | 2021-09-27 | Macular Degeneration | Details | |
| Bevacizumab biosimilar (Hetero Drugs) | Approved | Hetero Drugs Ltd | Cizumab | India | Colorectal Neoplasms | Hetero Drugs Ltd | 2016-06-27 | Colorectal Neoplasms | Details | |
| Bevacizumab biosimilar (Biocon/Mylan) | MYL-1402O | Approved | Biocon Ltd | KRABEVA, Abevmy, Lextemy | EU | Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Peritoneal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial | Mylan Ire Healthcare Ltd | 2017-11-27 | Ovarian Neoplasms; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Brain Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Bevacizumab biosimilar (Pfizer) | PF-6439535; PF-06439535 | Approved | Pfizer Inc | Zirabev | United States | Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Ovarian Epithelial | Pfizer Inc | 2019-02-14 | Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Neovasculgen | PI-VEGF165 | Approved | Human Stem Cells Institute | Neovasculgen | Russian Federation | Peripheral Arterial Disease | Human Stem Cells Institute | 2011-12-07 | Peripheral Arterial Disease; Peripheral Nerve Injuries | Details |
| Bevacizumab biosimilar (Allergan/Amgen) | ABP-215 | Approved | Amgen Inc | Mvasi | United States | Fallopian Tube Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms | Amgen Inc | 2017-09-14 | Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Bevacizumab biosimilar (Qilu Pharma) | QL-1101 | Approved | Qilu Pharmaceutical Co Ltd | 安可达 | Mainland China | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms | Qilu Pharmaceutical Co Ltd | 2019-12-06 | Colorectal Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung | Details |
| Bevacizumab biosimilar (Celltrion) | CTP-16; CT-16; CT-P16 | Approved | Celltrion Inc | Vegzelma | United States | Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Glioblastoma; Carcinoma, Renal Cell | Celltrion Inc | 2022-08-17 | Ovarian Neoplasms; Carcinoma, Renal Cell; Adenocarcinoma of Lung; Carcinoma, Ovarian Epithelial; Glioblastoma; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Ziv-aflibercept | BAY-865321; AVE-0005 | Approved | Regeneron Pharmaceuticals Inc, Sanofi | Zaltrap | Japan | Colorectal Neoplasms | Sanofi | 2012-08-03 | Lymphoma; Urethral Neoplasms; Breast Neoplasms; Brain Neoplasms; Colorectal Neoplasms; Carcinoma, Mucoepidermoid; Genital Neoplasms, Female; Gliosarcoma; Astrocytoma; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Ureteral Neoplasms; Peritoneal Neoplasms; Lung Neoplasms; Prostatic Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Neuroendocrine; Uterine Neoplasms; Endometrial Neoplasms; Glioma; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Thyroid Neoplasms; Retinal Vein Occlusion; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Leiomyosarcoma; Solid tumours; Multiple Endocrine Neoplasia Type 1; Leukemia; Rectal Neoplasms; Carcinoma; Carcinoma, Renal Cell; Carcinoid Tumor; Colonic Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Ovarian Neoplasms; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Carcinoma, Papillary; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Ascites; Lung Diseases; Adenoc | Details |
| Bevacizumab biosimilar (Jiangsu Hengrui Medicine) | BP-102 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾瑞妥 | Mainland China | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Suzhou Suncadia Biopharmaceuticals Co Ltd | 2021-06-22 | Solid tumours; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Conbercept | FP-3; KH-902 | Approved | Chengdu Kanghong Biotechnologies Co Ltd | 朗沐, Langmu | Mainland China | Macular Degeneration | Chengdu Kanghong Biotechnologies Co Ltd | 2013-11-27 | Macular Edema; Vision Disorders; Diabetic macular oedema; Wet Macular Degeneration; Retinoblastoma; Hemangioma; Uveitis; Corneal Neovascularization; Macular Degeneration; Choroidal Neovascularization; Diabetes Mellitus; Retinal Vein Occlusion | Details |
| Aflibercept | BAT-86-5321; BAY-865321 | Approved | Regeneron Pharmaceuticals Inc, Bayer AG | Eylea | Japan | Retinopathy of Prematurity | Bayer Yakuhin Ltd | 2011-11-18 | Diabetic macular oedema; Corneal Neovascularization; Choroidal Neovascularization; Retinal Vein Occlusion; Carcinoma, Non-Small-Cell Lung; Diabetic Retinopathy; Macular Degeneration; Retinopathy of Prematurity; Neoplasm Metastasis; Lymphoma, Non-Hodgkin; Retinal Degeneration; Eye Diseases; Vitreous Hemorrhage; Diabetes Complications; Colorectal Neoplasms; Retinitis Pigmentosa; Diabetes Mellitus, Type 1; Wet Macular Degeneration; Prostatic Neoplasms; Retinal Diseases; Multiple Myeloma; Myopia, Degenerative; Central Serous Chorioretinopathy; Colonic Neoplasms; Neoplasms; Choroid Diseases; Rectal Neoplasms; Glaucoma, Neovascular; Macular Edema; Diabetes Mellitus, Type 2; Cataract | Details |
| Bevacizumab | G180CU; RO-4876646; RG-435; NSC-704865; G180CL; R-435; G180DL | Approved | Genentech Inc | 安维汀, Avastin | Mainland China | Carcinoma, Hepatocellular | Shanghai Roche Pharmaceuticals Ltd | 2004-02-26 | Solid tumours; Pterygium; HIV Infections; Ependymoma; Ovarian Neoplasms; Kidney Neoplasms; Leiomyosarcoma; Fibrosarcoma; Liver Neoplasms; Epistaxis; Telangiectasia, Hereditary Hemorrhagic; Arteriovenous Malformations; Leukemia; Head and Neck Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macular Edema; Abdominal Neoplasms; Telangiectasis; Rectal Neoplasms; Carcinoma, Renal Cell; Meningeal Carcinomatosis; Hemangioblastoma; Esophageal Neoplasms; Anaplasia; Vaginal Neoplasms; Carcinoma; Esthesioneuroblastoma, Olfactory; Carcinoma, Basal Cell; Carcinoid Tumor; Diabetes Mellitus, Type 2; Granuloma, Lethal Midline; Squamous Cell Carcinoma of Head and Neck; Salivary Gland Neoplasms; Nasopharyngeal Neoplasms; Central Serous Chorioretinopathy; Adenocarcinoma of Lung; Glioblastoma; Colonic Neoplasms; Plasmacytoma; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Myelodysplastic Syndromes; Neurofibromatosis 2; Neoplasms; Blister; Fibrosis; Sepsis; Carcinoma, Verrucous; | Details |
| Ranibizumab | RG-3645; rhu-Fab-VEG; AMD-rhuFab-V2; AMD-Fab; rhuFab-V2; RFB-002; Y-0317; RG-6321 | Approved | Novartis Pharma Ag, Genentech Inc | Lucentis, 诺适得, Susvimo | Japan | Diabetic macular oedema | Novartis Pharma Ag | 2006-06-30 | Vitreous Hemorrhage; Retinoblastoma; Wet Macular Degeneration; Vascular Diseases; Glaucoma; Diabetes Complications; Pseudoxanthoma Elasticum; Retinal Detachment; Retinal Neovascularization; Cardiovascular Diseases; Eye Diseases; Uveitis; Ischemia; Hemangioma; Choroidal Neovascularization; Macular Degeneration; Melanoma; Conjunctival Neoplasms; Retinopathy of Prematurity; Retinal Vein Occlusion; Diabetic Retinopathy; Port-Wine Stain; Corneal Neovascularization; von Hippel-Lindau Disease; Diabetes Mellitus; Myopia; Telangiectasis; Epistaxis; Cataract; Telangiectasia, Hereditary Hemorrhagic; Pterygium; Retinal Telangiectasis; Diabetic Angiopathies; Vitreous Detachment; Iris Diseases; Macular Edema; Vision Disorders; Glaucoma, Neovascular; Choroid Diseases; Optic Neuropathy, Ischemic; Strongyloidiasis; Depression; Neovascularization, Pathologic; Central Serous Chorioretinopathy; Histoplasmosis; Myopia, Degenerative; Retinal Diseases; Angioid Streaks; Pathologic Processes; Glaucoma, Open-Angle; Diabetic macular oe | Details |
| Ranibizumab biosimilar (Xbrane) | Approved | Xbrane Biopharma Ab | EU | Wet Macular Degeneration; Diabetes Complications; Diabetic Retinopathy; Macular Edema | Stada Arzneimittel Ag | 2022-11-09 | Macular Edema; Wet Macular Degeneration; Diabetes Complications; Macular Degeneration; Diabetic Retinopathy | Details | ||
| Faricimab | RG-7716; RO-6867461 | Approved | F. Hoffmann-La Roche Ltd, Genentech Inc | Vabysmo | EU | Wet Macular Degeneration; Diabetes Complications; Macular Edema | Roche Registration Gmbh | 2022-01-28 | Macular Edema; Choroid Diseases; Diabetic macular oedema; Wet Macular Degeneration; Diabetes Complications; Diabetic Retinopathy; Diabetes Mellitus; Retinal Vein Occlusion; Macular Degeneration; Choroidal Neovascularization | Details |
| Bevacizumab biosimilar (mAbixience) | MB02; BEVZ-92; BEVZ92-MB02; AP-01 | Approved | Mabxience Sa | Alymsys | United States | Colorectal Neoplasms | Amneal Pharmaceuticals Llc | 2013-10-25 | Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Bevacizumab biosimilar (Betta/Mabworks) | MIL-60 | Approved | Institute Of Basic Medicine, Chinese Academy Of Medical Sciences, Beijing Mabworks Biotech Co Ltd | 贝安汀 | Mainland China | Glioblastoma; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Ovarian Epithelial | Betta Pharmaceuticals Co Ltd | 2021-11-24 | Glioblastoma; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular | Details |
| Bevacizumab biosimilar (Bio-Thera Solutions) | BAT-1706 | Approved | Bio-Thera Solutions Ltd | 普贝希 | Mainland China | Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Glioblastoma; Peritoneal Neoplasms; Uterine Cervical Neoplasms | Bio-Thera Solutions Ltd | 2021-11-17 | Ovarian Neoplasms; Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular | Details |
| Bevacizumab biosimilar (Boan Biopharma) | LY-01008 | Approved | Shandong Boan Biotechnology Co Ltd | 博优诺 | Mainland China | Uterine Cervical Neoplasms; Carcinoma, Ovarian Epithelial | Shandong Boan Biotechnology Co Ltd | 2021-05-07 | Glioblastoma; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms | Details |
| Bevacizumab biosimilar (Shanghai Henlius Biotech) | HLX-04; HLX04-O | Approved | Shanghai Henlius Biotech Co Ltd | 汉贝泰 | Mainland China | Glioblastoma; Carcinoma, Hepatocellular | Shanghai Henlius Biotech Co Ltd | 2021-11-30 | Solid tumours; Carcinoma; Rectal Neoplasms; Glioblastoma; Carcinoma, Ovarian Epithelial; Wet Macular Degeneration; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Macular Degeneration; Carcinoma, Hepatocellular | Details |
| Bevacizumab biosimilar (TOT Biopharm) | TAB-008; TOT-102; TAB008; TOT102 | Approved | Tot Biopharm Co Ltd | 朴欣汀, Pusintin | Mainland China | Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Glioblastoma; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms | Tot Biopharm Co Ltd | 2021-12-01 | Carcinoma, Ovarian Epithelial; Glioblastoma; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Ranibizumab biosimilar (Formycon/Bioeq) | FYB-201 | Approved | Formycon, Bioeq Gmbh | CIMERLI, Ranivisio | EU | Macular Edema; Choroidal Neovascularization; Diabetic Retinopathy; Wet Macular Degeneration; Diabetes Complications | Midas Pharma Gmbh | 2022-08-02 | Macular Edema; Wet Macular Degeneration; Diabetic macular oedema; Diabetes Complications; Choroidal Neovascularization; Macular Degeneration; Retinal Vein Occlusion; Diabetic Retinopathy | Details |
| Bevacizumab biosimilar (Samsung Bioepis) | SP-8; SB-8 | Approved | Samsung Bioepis Co Ltd | Aybintio | EU | Uterine Cervical Neoplasms; Carcinoma, Renal Cell; Fallopian Tube Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Samsung Bioepis Nl Bv | 2020-08-19 | Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Ranibizumab biosimilar (Samsung Bioepis) | SB-11 | Approved | Samsung Bioepis Co Ltd | BYOOVIZ | United States | Macular Degeneration; Macular Edema; Choroidal Neovascularization | Samsung Bioepis Co Ltd | 2021-08-18 | Macular Edema; Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration; Diabetic Retinopathy; Choroidal Neovascularization; Retinal Vein Occlusion | Details |
| Bevacizumab biosimilar (Innovent Biologics) | IBI-305; IBI305; IBI 305; CHS-305 | Approved | Innovent Biologics(Suzhou) Co Ltd | 达攸同, BYVASDA, Bevagen | Indonesia | Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Uterine Cervical Neoplasms; Colorectal Neoplasms | Innovent Biologics(Suzhou) Co Ltd | 2020-06-17 | Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Glioblastoma; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Ranibizumab biosimilar (CJSC Generium) | GNR-067 | Phase 1 Clinical | Cjsc Generium | Macular Degeneration | Details |
| Colorectal cancer vaccine (Immunovo/Pepscan Therapeutics) | Phase 1 Clinical | Pepscan Systems | Colorectal Neoplasms | Details | |
| Ranibizumab biosimilar (Reliance Life Sciences Group) | R-TPR-024 | Phase 3 Clinical | Reliance Life Sciences | Macular Degeneration | Details |
| SCT-501(National Cancer Institute) | SCT-501 | Phase 2 Clinical | National Cancer Institute | Kidney Neoplasms | Details |
| Ziv-aflibercept biosimiliar (Boan Biopharma) | LY-01012; BA-1103 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Colorectal Neoplasms | Details |
| Bevacizumab biosimilar (Gedeon Richter) | Phase 1 Clinical | Gedeon Richter Plc | Neoplasms | Details | |
| Aflibercept biosimilar (Amgen) | ABP-938 | Phase 2 Clinical | Amgen Inc | Macular Degeneration | Details |
| Bevacizumab biosimilar(Guangdong Dongyangguang) | Phase 1 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | |
| Bevacizumab biosimilar (Shanghai Kangdai) | Phase 1 Clinical | Shanghai Kanda Bio-Technology Co Ltd | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| Bevacizumab biosimilar (Tanvex BioPharma) | TX-16 | Phase 1 Clinical | Tanvex Biopharma | Colorectal Neoplasms | Details |
| Bevacizumab biosimilar(Guilin Sanjin) | Phase 1 Clinical | Guilin Sanjin Pharmaceutical Co Ltd | Macular Degeneration | Details | |
| Bevacizumab biosimilar(Bioxpress) | BXT-2316 | Clinical | Bioxpress Therapeutics Sa | Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| Aflibercept biosimilar (Zein Bioteccnology) | Phase 1 Clinical | Zein Bioteccnology Co Ltd | Diabetic macular oedema | Details | |
| CLS-1002 | CLS-1002 | Phase 1 Clinical | Clearside Biomedical Inc | Macular Degeneration | Details |
| Ranibizumab biosimilar (Pfenex) | PF-582 | Pfenex | Details | ||
| Aflibercept biosimilar (Sam Chun Dang Pharm) | SCD-411 | Sam Chun Dang Pharm Co Ltd | Details | ||
| FYB-203 | FYB-203 | Formycon | Details | ||
| Aflibercept biosimilar (Mabwell) | 9-MW-0813; 9MW-0813; 9MW0813; 9-MW0813 | Phase 3 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Diabetic macular oedema | Details |
| DE-120 | DE-120 | Santen | Details | ||
| AG-13958 | AG-13958; AG-013958 | Pfizer Inc | Details | ||
| Ranibizumab biosimilar (Qilu Pharmaceutical) | BCD-300; QL-1205 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd, Biocnd | Wet Macular Degeneration; Macular Degeneration | Details |
| Ranibizumab biosimilar (Chong Kun Dang Pharmaceutical) | CKD-701 | Chong Kun Dang Pharmaceutical Corp | Details | ||
| SNN-0029 | sNN-0029 | Newron Pharmaceutical | Details | ||
| Bevacizumab biosimilar (Boehringer Ingelheim) | BI-695502 | C.H. Boehringer Sohn Ag & Co. Kg | Details | ||
| Ranibizumab biosimilar (Lupin) | LUBT-010 | Phase 3 Clinical | Rubin Ltd | Macular Degeneration | Details |
| Bevacizumab biosimilar (North China Pharmaceutical) | MG-021 | Phase 1 Clinical | North China Pharmaceutical Company Ltd | Colorectal Neoplasms; Macular Degeneration; Carcinoma, Non-Small-Cell Lung | Details |
| Dilpacimab | ABT-165; DVD-Ig ABT-165 | Phase 1 Clinical | Abbvie Inc | Solid tumours; Neoplasms | Details |
| ALS-L1023 | ALS-L1023 | Phase 2 Clinical | Angiolab Inc | Non-alcoholic Fatty Liver Disease; Metabolic Syndrome; Macular Degeneration | Details |
| OB-318 | OB-318 | Phase 1 Clinical | Oneness Biotech Co Ltd | Solid tumours; Carcinoma, Hepatocellular | Details |
| Bevacizumab biosimilar(Zhejiang Teruisi Pharmaceutical) | TRS-003 | Phase 3 Clinical | Zhejiang Teruisi Pharmaceutical Inc | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Varisacumab | R-84; GNR-011; AT-001-IBCG | Phase 3 Clinical | Peregrine, The University Of Texas Southwestern Medical Center | Glioblastoma; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| IBI-324 | IBI-324 | Phase 1 Clinical | Innovent Biologics (Usa), Inc | Diabetic macular oedema | Details |
| Ranibizumab biosimilar (Shanghai United Cell Biotechnology) | Phase 1 Clinical | Shanghai United Cell Biotechnology Co Ltd | Macular Edema; Macular Degeneration | Details | |
| MP-0250 | MP-0250 | Phase 2 Clinical | Molecular Partners Ag | Neoplasms; Multiple Myeloma; Carcinoma, Non-Small-Cell Lung | Details |
| CT-P42 | CT-P42 | Phase 3 Clinical | Celltrion Inc | Diabetic macular oedema | Details |
| Aflibercept Biosimilar (Alteogen) | ALT-L9 | Phase 3 Clinical | Alteogen Inc, Kissei Pharmaceutical Co Ltd | Macular Degeneration | Details |
| Bevacizumab biosimilar (Genor Biopharma) | GB-222 | Phase 3 Clinical | Genor Biopharma Co Ltd | Brain Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Bevacizumab biosimilar (Alphamab/R-Pharm) | RPH-001 | Phase 3 Clinical | R-Pharm | Colorectal Neoplasms | Details |
| Bevacizumab biosimilar (Beijing Science Sun/Beijing Lvzhu) | K-11 | Phase 3 Clinical | Beijing Lvzhu Biological Technology Co Ltd, Beijing Science Sun Pharmaceutical Co Ltd | Liver Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
| Bevacizumab biosimilar (Centus Biotherapeutics) | FKB-238 | Phase 3 Clinical | Fujifilm Kyowa Kirin Biologics Co Ltd | Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| ASKG-712 | AM-712; ASKG-712 | Phase 1 Clinical | Wet Macular Degeneration; Macular Degeneration | Details | |
| Bevacizumab biosimilar(Laboratorios Sophia) | PRO-169 | Phase 3 Clinical | Laboratorios Sophia Sa De Cv | Diabetic macular oedema | Details |
| Aflibercept Biosimilar(Alvotech Swiss) | AVT-06 | Phase 3 Clinical | Alvotech Swiss Ag | Macular Degeneration | Details |
| Sevacizumab | SIM-BD-0801; EPI-0030; BD-0801; TK-001; APX-003; 9MW0211; 9MW-0211; MW02; MW-02 | Phase 3 Clinical | Epitomics Inc, Apexigen Inc | Ovarian Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Wet Macular Degeneration; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Macular Degeneration | Details |
| VEGFA-targeting Gene Therapy(BDgene) | BD311 | Phase 1 Clinical | Shanghai BDgene Technology Co Ltd | Diabetic macular oedema; Macular Degeneration; Retinal Vein Occlusion | Details |
| Muparfostat sodium | PI-88 | Phase 3 Clinical | Australian National University | Solid tumours; Liver Neoplasms; Neoplasms; Prostatic Neoplasms; Lung Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| Emvododstat | PTC-299 | Phase 3 Clinical | Ptc Therapeutics Inc | Pneumonia; Neoplasms; Neurofibromatosis 2; Coronavirus Disease 2019 (COVID-19); Central Nervous System Neoplasms; Brain Neoplasms; Breast Neoplasms; Coronavirus Infections; Leukemia, Myeloid, Acute; Sarcoma, Kaposi | Details |
| Vanucizumab | RG-7221; RO-5520985; B800Z06O8K (UNII code) | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Neoplasms; Colorectal Neoplasms | Details |
| Aflibercept biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Macular Degeneration | Details | |
| Bevacizumab biosimilar (Eastern Biotech) | JY-028 | Phase 2 Clinical | Beijing Eastern Biotech Co Ltd | Wet Macular Degeneration; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Macular Degeneration | Details |
| IBI-333 | IBI-333 | Phase 1 Clinical | Innovent Biologics (Usa), Inc | Wet Macular Degeneration; Macular Degeneration | Details |
| Aflibercept biosimilar (Momenta/Mylan) | M-710; MYL-1701P | Phase 3 Clinical | Mylan Nv, Momenta | Diabetic macular oedema | Details |
| TR-009 | NOV-1501; ABL001-ABL Bio; ABL-001-ABL Bio; ES-104; CTX-009 | Phase 3 Clinical | Abl Bio Inc | Biliary Tract Neoplasms; Solid tumours; Rectal Neoplasms; Colonic Neoplasms; Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Bile Duct Neoplasms; Gallbladder Neoplasms | Details |
| BI-836880 | BI-836880 | Phase 2 Clinical | Ablynx Nv | Neoplasms; Wet Macular Degeneration | Details |
| Bevacizumab biosimilar (Hualan Biological Engineering) | WBP-264 | Phase 3 Clinical | Hualan Genetic Engineering Co Ltd | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| ELGN-EYE | ELGN-EYE | Phase 2 Clinical | Elgan Pharma Ltd | Retinopathy of Prematurity | Details |
| Bevacizumab biosimilar (JHL Biotech) | JHL-1149 | Phase 1 Clinical | JHL Biotech | Neoplasms | Details |
| Bevacizumab biosimilar(Shanghai Institute Of Biological Products) | SIBP-04 | Phase 1 Clinical | Shanghai Institute Of Biological Products Co Ltd | Details | |
| Aflibercept Biosimilar (Boan Biopharma/Luye Pharma） | LY-09004; BA-9101; OT-702 | Phase 3 Clinical | Shandong Boan Biotechnology Co Ltd, Luye Pharma Group Ltd | Wet Macular Degeneration; Macular Degeneration | Details |
| Aflibercept biosimilar (Samsung Bioepis) | SB-15 | Phase 3 Clinical | Samsung Bioepis Co Ltd | Macular Degeneration | Details |
| Bevacizumab biosimilar (Prestige BioPharma/Hanwha Biologics) | HD-204 | Phase 3 Clinical | Hanwha Biologics | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Bevacizumab biosimilar (Huaota Biopharm) | JS-501; HOT-1010 | Phase 3 Clinical | Shanghai Huaota Biopharmaceutical Co Ltd, Shanghai Junshi Biosciences Co Ltd | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Bevacizumab biosimilar (Fudan-Zhangjiang) | Phase 3 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Colorectal Neoplasms; Macular Degeneration; Carcinoma, Non-Small-Cell Lung | Details | |
| Bevacizumab biosimilar(Jiangsu Aosaikang) | ASK-1202; AMD-B; AK-3008; ASK-B1202; ASKB1202 | Phase 3 Clinical | Jiangsu Aosaikang Pharmaceutical Co Ltd | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.
A-Z
